Syndax Competitors

Stocks . USA . 
Stock . Syndax Pharmaceuticals
SNDX Stock  USD 20.55  0.76  3.57%   
Syndax Pharmaceuticals competes with Relay Therapeutics, Inhibrx Biosciences, Amylyx Pharmaceuticals, Oric Pharmaceuticals, and Nektar Therapeutics; as well as few others. The company conducts business under Biotechnology sector and is part of Health Care industry. Analyzing Syndax Pharmaceuticals competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Syndax Pharmaceuticals to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Syndax Pharmaceuticals Correlation with its peers.
For more information on how to buy Syndax Stock please use our How to Invest in Syndax Pharmaceuticals guide.

Syndax Pharmaceuticals vs Zenas BioPharma Correlation

Good diversification

The correlation between Syndax Pharmaceuticals and ZBIO is -0.19 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Syndax Pharmaceuticals and ZBIO in the same portfolio, assuming nothing else is changed.

Moving against Syndax Stock

  0.71NIO Nio Class APairCorr
  0.55GRAB Grab HoldingsPairCorr
  0.35NVDA NVIDIA Aggressive PushPairCorr
  0.32PG Procter GamblePairCorr
Specify up to 10 symbols:
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Syndax Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
16.7220.5524.38
Details
Intrinsic
Valuation
LowRealHigh
18.8622.6926.52
Details
Naive
Forecast
LowNextHigh
17.1120.9424.77
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
19.9220.9021.88
Details

Syndax Pharmaceuticals Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Syndax Pharmaceuticals and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Syndax and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Syndax Pharmaceuticals does not affect the price movement of the other competitor.

High positive correlations

CVAC
+ 0.7
INBX
ZBIO
+ 0.67
INBX
ZBIO
+ 0.66
CVAC
ORIC
+ 0.64
AMLX
ZBIO
+ 0.59
NKTR
NKTR
+ 0.51
ORIC
  

High negative correlations

ORIC
- 0.71
RLAY
NKTR
- 0.49
RLAY
CVAC
- 0.4
ORIC
ZBIO
- 0.28
SANA
SANA
- 0.18
NKTR
SANA
- 0.18
INBX

Risk-Adjusted Indicators

There is a big difference between Syndax Stock performing well and Syndax Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Syndax Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
RLAY  3.05  0.22  0.06  0.30  3.39 
(3.42)
 6.11 
(5.45)
 27.25 
INBX  2.75 (0.11) 0.00  1.45  0.00 
 0.00 
 5.85 
(5.44)
 17.82 
AMLX  2.84  0.07  0.01  0.30  3.11 
(3.22)
 8.11 
(5.24)
 20.49 
ORIC  2.81 (0.14) 0.00 (0.32) 0.00 
 0.00 
 6.63 
(4.48)
 15.34 
NKTR  3.66 (0.76) 0.00 (0.87) 0.00 
 0.00 
 6.56 
(7.77)
 20.31 
SANA  4.35 (0.29) 0.00 (0.05) 0.00 
 0.00 
 12.59 
(8.77)
 25.63 
IMTX  2.99 (0.06) 0.00 (0.08) 0.00 
 0.00 
 7.31 
(6.47)
 30.34 
CVAC  1.61 (0.26) 0.00  4.01  0.00 
 0.00 
 3.63 
(3.60)
 18.10 
ATAI  2.66 (0.65) 0.00 (1.43) 0.00 
 0.00 
 4.91 
(5.54)
 15.15 
ZBIO  5.89  0.45  0.03 (0.28) 11.16 
(5.78)
 13.19 
(8.49)
 84.91 

Syndax Pharmaceuticals Competitive Analysis

The better you understand Syndax Pharmaceuticals competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Syndax Pharmaceuticals' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Syndax Pharmaceuticals' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
SNDX RLAY INBX AMLX ORIC NKTR SANA IMTX CVAC ATAI
 3.57 
 20.55 
Syndax
 10.00 
 7.65 
Relay
 0.67 
 73.98 
Inhibrx
 6.21 
 14.51 
Amylyx
 9.33 
 10.98 
Oric
 1.89 
 35.23 
Nektar
 3.16 
 4.60 
Sana
 3.30 
 9.38 
Immatics
 0.00 
 4.66 
CureVac
 0.78 
 3.84 
ATAI
Market Volatility
(90 Days Market Risk)
Not too volatile
Moderately volatile
Very steady
Somewhat reliable
Somewhat reliable
Not too volatile
Very risky
Slightly risky
Moderately volatile
Unstable
Market Performance
(90 Days Performance)
Good
Soft
Weakest
Weak
Weakest
Weakest
Weakest
Weakest
Weakest
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Small
Low
Low
Fair
High
Risky
Average
Low
Low
Low
Current Valuation
(Equity Enterprise Value)
Under Valued
Over Valued
Over Valued
Over Valued
Under Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Fairly Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Strong Buy
Not Available
Strong Buy
Strong Buy
Buy
Strong Buy
Strong Buy
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Buy
Strong Hold
Strong Sell
Strong Sell
Sell
Strong Sell
Strong Sell
Strong Sell
Not Rated
Strong Sell
Current Ratio
17.19
15.22
7.51
7.96
18.72
7.14
5.09
2.95
3.61
12.25
Net Asset
724.82 M
871.3 M
180.77 M
193.63 M
274.14 M
303.85 M
501.02 M
696.15 M
802.83 M
159.39 M
Profit Margin
-2.8
N/A
N/A
N/A
N/A
-1.93
N/A
-1.42
1.82
N/A
EBITDA
(313.82 M)
(380.21 M)
1.7 B
(290.98 M)
(126.74 M)
(86.7 M)
(255.33 M)
34.46 M
209.69 M
(144.81 M)
Operating Margin
-1.25
-38.87
-21.07
291.04
N/A
-2.67
N/A
-10.53
5.73
-37.97
Current Valuation
1.4 B
761.95 M
428.15 M
1.25 B
785.5 M
552.17 M
1.2 B
802.39 M
599.28 M
1.3 B
Price To Book
16.05
2.18
7.41
4.8
2.63
8.59
6.49
2.6
1.03
8.87
Retained Earnings
(1.22 B)
(1.74 B)
(106.13 M)
(606.69 M)
(562.77 M)
(3.6 B)
(1.6 B)
(589.54 M)
(1.4 B)
(700.21 M)
Current Asset
79.72 M
N/A
N/A
N/A
N/A
350.05 M
N/A
N/A
N/A
320.15 M
One Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.48
1.56
2.88
-0.31
1.36
1.32
1.97
1.36
1.84
1.62
Number Of Employees
270
188
156
123
106
61
194
645
825
54
Equity Positions Weight
N/A
N/A
N/A
50.03
N/A
N/A
N/A
N/A
N/A
N/A
Shares Outstanding
86.91 M
173.32 M
14.49 M
109.82 M
97.39 M
20.34 M
266.37 M
134.06 M
225.17 M
363.21 M
Three Year Return
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash Flow From Operations
(274.9 M)
(249.11 M)
(194.41 M)
(167.65 M)
(112.66 M)
(175.71 M)
(223.15 M)
(158.03 M)
101.85 M
(82.44 M)
Total Debt
345.74 M
48.5 M
8.05 M
1.98 M
3.18 M
102.56 M
94.2 M
16.2 M
38.97 M
24.71 M
Return On Equity
-1.29
-0.41
-1.14
-0.57
-0.4
-1.8
-0.96
-0.3
0.4
-1.01
Return On Asset
-0.39
-0.25
-0.26
-0.39
-0.25
-0.28
-0.24
-0.16
0.24
-0.29
Number Of Shares Shorted
22.34 M
22.38 M
1.65 M
13.44 M
21.14 M
3.26 M
37.11 M
5.37 M
547.32 K
14.59 M
Book Value Per Share
1.33
3.52
4.74
3.03
4.18
4.33
0.75
4.11
5.63
0.66
Current Liabilities
13.32 M
N/A
N/A
N/A
N/A
61.25 M
N/A
N/A
N/A
74.35 M
Total Asset
724.82 M
871.3 M
180.77 M
193.63 M
274.14 M
303.85 M
501.02 M
696.15 M
802.83 M
159.39 M
Debt To Equity
0.003
0.06
4.22
0.036
0.054
0.33
0.18
0.13
0.066
0.057
Short Ratio
14.53
10.46
6.46
7.51
12.1
3.24
10.92
12.12
0.32
4.0
Target Price
39.31
14.55
12.0
20.22
21.0
114.43
8.71
19.13
5.41
12.27
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
98.73
97.97
65.51
92.44
93.29
71.58
77.8
77.11
10.43
28.2
Market Capitalization
1.85 B
1.34 B
486.86 M
1.59 B
1.07 B
716.63 M
1.27 B
1.26 B
1.05 B
1.42 B
Price To Earning
126.11
N/A
N/A
N/A
N/A
8.02
N/A
44.61
N/A
0.3
Price To Earnings To Growth
N/A
0.07
N/A
-0.15
N/A
3.22
N/A
3.0
0.07
N/A
Price To Sales
16.64
159.94
347.75
4.44
N/A
11.45
N/A
14.84
14.83
469.36
Net Income
(318.76 M)
(337.71 M)
1.69 B
(301.74 M)
(127.85 M)
(118.96 M)
(266.76 M)
15.22 M
190.88 M
(150.05 M)
Earnings Per Share
-3.6
-1.72
-16.57
-1.79
-1.71
-9.83
-0.96
-1.12
0.67
-0.83
Shares Owned By Insiders
1.27
1.32
27.17
7.56
6.71
0.83
6.96
18.8
0.09
3.69
Revenue
23.68 M
10.01 M
200 K
87.37 M
N/A
98.43 M
N/A
155.84 M
535.18 M
308 K
Working Capital
499.51 M
758.48 M
119.67 M
161.03 M
237.4 M
199.89 M
115.38 M
561.57 M
454.07 M
55.17 M
Cash And Equivalents
350.71 M
1.05 B
176.38 M
206.68 M
227.06 M
546.39 M
484.8 M
324.38 M
540.87 M
304.06 M
Cash Per Share
5.82
8.72
4.52
3.53
5.74
2.91
2.57
5.0
2.85
1.83
Gross Profit
(133.23 M)
(259.24 M)
(171.77 M)
(92.75 M)
N/A
54.62 M
N/A
(91.28 M)
65.99 M
2.53 M
Day Typical Price
20.82
7.92
74.21
14.89
11.35
35.42
4.68
9.51
4.66
3.88
Accumulation Distribution
0.0425
0.1
0.0624
0.0783
0.0965
18984.19
111164.0
18929.68
N/A
178116.0
Market Facilitation Index
0.91
0.87
4.79
1.23
1.17
0.0
N/A
0.0
N/A
N/A
Daily Balance Of Power
(0.84)
(0.98)
0.1023
(0.78)
(0.97)
(0.49)
(0.56)
(0.64)
0.0
(0.14)
Period Momentum Indicator
(0.76)
(0.85)
0.49
(0.96)
(1.13)
(0.68)
(0.15)
(0.32)
N/A
(0.03)
Rate Of Daily Change
0.96
0.9
1.01
0.94
0.91
0.98
0.97
0.97
1.0
0.99
Day Median Price
20.96
8.06
74.33
15.09
11.54
35.51
4.72
9.57
4.66
3.9
Price Action Indicator
(0.78)
(0.83)
(0.10)
(1.06)
(1.12)
(0.62)
(0.20)
(0.35)
N/A
(0.07)
Relative Strength Index
55.42
48.99
46.14
53.76
51.22
35.43
48.69
45.57
43.87
39.5
Coefficient Of Variation
520.51
1580.45
(3,502)
4101.79
(3,357)
(642.73)
(4,336)
(16,905)
(1,102)
(611.68)
Mean Deviation
2.79
3.05
2.75
2.84
2.81
3.66
4.35
2.99
1.61
2.66
Jensen Alpha
0.6955
0.2243
(0.11)
0.0732
(0.14)
(0.76)
(0.29)
(0.06)
(0.26)
(0.65)
Total Risk Alpha
0.4554
(0.04)
(0.36)
(0.20)
(0.40)
(1.03)
(0.55)
(0.35)
(0.46)
(0.89)
Sortino Ratio
0.3027
0.0601
N/A
0.0116
N/A
N/A
N/A
N/A
N/A
N/A
Downside Variance
4.97
13.3
N/A
10.06
N/A
N/A
N/A
N/A
N/A
N/A
Standard Deviation
3.83
4.43
3.52
4.03
3.84
4.52
5.79
4.49
2.81
3.76
Kurtosis
2.86
6.45
0.3017
3.44
1.49
(0.36)
0.5838
4.26
13.57
3.31
Potential Upside
8.7
6.11
5.85
8.11
6.63
6.56
12.59
7.31
3.63
4.91
Treynor Ratio
1.22
0.2999
1.45
0.3015
(0.32)
(0.87)
(0.05)
(0.08)
4.01
(1.43)
Maximum Drawdown
18.37
27.25
17.82
20.49
15.34
20.31
25.63
30.34
18.1
15.15
Variance
14.68
19.66
12.36
16.22
14.77
20.46
33.52
20.13
7.89
14.1
Market Risk Adjusted Performance
1.23
0.3099
1.46
0.3115
(0.31)
(0.86)
(0.04)
(0.07)
4.02
(1.42)
Risk Adjusted Performance
0.1476
0.0543
(0.01)
0.0259
(0.01)
(0.10)
(0.01)
0.0041
(0.06)
(0.11)
Skewness
1.53
1.54
(0.30)
1.43
0.5166
(0.16)
0.753
0.8147
(2.77)
(0.57)
Semi Deviation
1.89
3.39
N/A
3.11
N/A
N/A
N/A
N/A
N/A
N/A
Information Ratio
0.1761
0.0494
(0.05)
0.0092
(0.05)
(0.17)
(0.03)
(0.02)
(0.11)
(0.18)
Value At Risk
(3.57)
(5.45)
(5.44)
(5.24)
(4.48)
(7.77)
(8.77)
(6.47)
(3.60)
(5.54)
Expected Short fall
(3.97)
(3.42)
N/A
(3.22)
N/A
N/A
N/A
N/A
N/A
N/A
Downside Deviation
2.23
3.65
N/A
3.17
N/A
N/A
N/A
N/A
N/A
N/A
Semi Variance
3.56
11.49
N/A
9.67
N/A
N/A
N/A
N/A
N/A
N/A

Syndax Pharmaceuticals Competition Performance Charts

Five steps to successful analysis of Syndax Pharmaceuticals Competition

Syndax Pharmaceuticals' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Syndax Pharmaceuticals in relation to its competition. Syndax Pharmaceuticals' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Syndax Pharmaceuticals in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Syndax Pharmaceuticals' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Syndax Pharmaceuticals, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Syndax Pharmaceuticals position

In addition to having Syndax Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Blockchain Thematic Idea Now

Blockchain
Blockchain Theme
Companies across muliple sectors and different technology products and services that are engaged in some capacity with blockchain technolgoy or evolution of cryptocurrency. The Blockchain theme has 28 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Blockchain Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Syndax Stock Analysis

When running Syndax Pharmaceuticals' price analysis, check to measure Syndax Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Syndax Pharmaceuticals is operating at the current time. Most of Syndax Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Syndax Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Syndax Pharmaceuticals' price. Additionally, you may evaluate how the addition of Syndax Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY